Theodore

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9832094/publications.pdf

Version: 2024-02-01

56 3,888 26 54 papers citations h-index g-index

56 56 56 2941 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. Lancet Infectious Diseases, The, 2022, 22, e178-e190.	9.1	51
2	Nontuberculous Mycobacterial Disease Epidemiology: You Can See the Stars and Still Not See the Light. Clinical Infectious Diseases, 2021, 73, e327-e329.	5.8	2
3	Aspergillus isolation in nontuberculous mycobacterial pulmonary disease: Associated with antimycobacterial treatment initiation but not response. Respiratory Medicine, 2021, 179, 106338.	2.9	2
4	Hospitalization Risk for Medicare Beneficiaries With Nontuberculous Mycobacterial Pulmonary Disease. Chest, 2021, 160, 2042-2050.	0.8	3
5	Treatment outcomes of nontuberculous mycobacterial pulmonary disease in lung transplant recipients. Transplant Infectious Disease, 2021, 23, e13679.	1.7	1
6	Clofazimine Drug Susceptibility Testing for Nontuberculous Mycobacteria. Chest, 2021, 160, e90.	0.8	0
7	Amikacin Liposome Inhalation Suspension for <i>Mycobacterium avium</i> Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial. Annals of the American Thoracic Society, 2021, 18, 1147-1157.	3.2	29
8	Clinical Considerations for Routine Auditory and Vestibular Monitoring in Patients With Cystic Fibrosis. American Journal of Audiology, 2021, 30, 800-809.	1.2	8
9	Incidence and Prevalence of Nontuberculous Mycobacterial Lung Disease in a Large U.S. Managed Care Health Plan, 2008–2015. Annals of the American Thoracic Society, 2020, 17, 178-185.	3.2	159
10	Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clinical Infectious Diseases, 2020, 71, 905-913.	5.8	357
11	Clinical outcomes in Mycobacterium xenopi versus Mycobacterium avium complex pulmonary disease: A retrospective matched cohort study. Respiratory Medicine, 2020, 167, 105967.	2.9	9
12	The impact of different antibiotic treatment regimens on mortality in Mycobacterium avium complex pulmonary disease: a population-based cohort study. European Respiratory Journal, 2020, 56, 1901875.	6.7	2
13	Outcomes of a Peri- and Postoperative Management Protocol for Non-TB Mycobacteria in Lung Transplant Recipients. Chest, 2020, 158, 523-528.	0.8	4
14	Clinical efficacy and safety of fluoroquinolone containing regimens in patients with Mycobacterium avium complex pulmonary disease. European Respiratory Journal, 2020, 55, 1901240.	6.7	6
15	Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. European Respiratory Journal, 2020, 56, 2000535.	6.7	336
16	Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clinical Infectious Diseases, 2020, 71, e1-e36.	5.8	367
17	Sputum smear microscopy predicting mycobacterial culture in Ontario: A population-based laboratory report. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2019, 3, 39-42.	0.5	O
18	Guidelines-based treatment associated with improved economic outcomes in nontuberculous mycobacterial lung disease. Journal of Medical Economics, 2019, 22, 1126-1133.	2.1	8

#	Article	IF	Citations
19	Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada. BMC Pharmacology & Expression (2019, 20, 37).	2.4	16
20	Radiologic types of Mycobacterium xenopi pulmonary disease: different patients with similar short-term outcomes. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 373-381.	2.9	6
21	Procedure volume and mortality after surgical lung biopsy in interstitial lungÂdisease. European Respiratory Journal, 2019, 53, 1801164.	6.7	54
22	Mycobacterium xenopi Genotype Associated with Clinical Phenotype in Lung Disease. Lung, 2018, 196, 213-217.	3.3	7
23	Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. European Respiratory Journal, 2018, 51, 1800170.	6.7	159
24	Characteristics, treatment and outcomes of nontuberculous mycobacterial pulmonary disease after allogeneic haematopoietic stem cell transplant. European Respiratory Journal, 2018, 51, 1702330.	6.7	11
25	Incidence and Risk Factors for Nontuberculous Mycobacterial Infection after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 366-372.	2.0	30
26	Relative risk of all-cause mortality in patients with nontuberculous mycobacterial lung disease in a US managed care population. Respiratory Medicine, 2018, 145, 80-88.	2.9	33
27	Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by <i>Mycobacterium avium</i> Complex (CONVERT). A Prospective, Open-Label, Randomized Study. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1559-1569.	5.6	206
28	Health Care Utilization and Expenditures Following Diagnosis of Nontuberculous Mycobacterial Lung Disease in the United States. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 964-974.	0.9	15
29	Long-Term Outcomes in a Population-based Cohort with Respiratory Nontuberculous Mycobacteria Isolation. Annals of the American Thoracic Society, 2017, 14, 1120-1128.	3.2	17
30	The risk of mycobacterial infections associated with inhaled corticosteroid use. European Respiratory Journal, 2017, 50, 1700037.	6.7	122
31	Pulmonary Nontuberculous Mycobacteria–Associated Deaths, Ontario, Canada, 2001–2013. Emerging Infectious Diseases, 2017, 23, 468-476.	4.3	64
32	The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry. Canadian Respiratory Journal, 2016, 2016, 1-7.	1.6	45
33	Healthâ€related quality of life, comorbidities and mortality in pulmonary nontuberculous mycobacterial infections: A systematic review. Respirology, 2016, 21, 1015-1025.	2.3	23
34	Patient-Centered Research Priorities for Pulmonary Nontuberculous Mycobacteria (NTM) Infection. An NTM Research Consortium Workshop Report. Annals of the American Thoracic Society, 2016, 13, S379-S384.	3.2	58
35	Risk of nontuberculous mycobacterial pulmonary disease with obstructive lung disease. European Respiratory Journal, 2016, 48, 928-931.	6.7	32
36	Impact of pulmonary nontuberculous mycobacterial treatment on pulmonary function tests in patients with and without established obstructive lung disease. Respirology, 2015, 20, 987-993.	2.3	9

#	Article	IF	CITATIONS
37	Epidemiology of Human Pulmonary Infection with Nontuberculous Mycobacteria. Clinics in Chest Medicine, 2015, 36, 13-34.	2.1	665
38	Increased risk of mycobacterial infections associated with anti-rheumatic medications. Thorax, 2015, 70, 677-682.	5 . 6	134
39	Variable agreement among experts regarding <scp><i>M</i></scp> <i>ycobacterium avium</i> complex lung disease. Respirology, 2015, 20, 348-351.	2.3	17
40	Nonâ€tuberculous mycobacterial infections at <scp>S</scp> an <scp>F</scp> rancisco <scp>G</scp> eneral <scp>H</scp> ospital. Clinical Respiratory Journal, 2015, 9, 436-442.	1.6	8
41	Multilocus Sequence Typing of Mycobacterium xenopi. Journal of Clinical Microbiology, 2014, 52, 3973-3977.	3.9	5
42	Lung Function and Survival in Systemic Sclerosis Interstitial Lung Disease. Journal of Rheumatology, 2014, 41, 2326-2328.	2.0	10
43	Risk of Mycobacterial Infections Associated With Rheumatoid Arthritis in Ontario, Canada. Chest, 2014, 146, 563-572.	0.8	55
44	Opinions Differ by Expertise in Mycobacterium avium Complex Disease. Annals of the American Thoracic Society, 2014, 11, 17-22.	3.2	15
45	Comparison of the Spectrum of Radiologic and Clinical Manifestations of Pulmonary Disease Caused by <i>Mycobacterium avium </i> Complex and <i>Mycobacterium xenopi </i> Radiologists Journal, 2014, 65, 207-213.	2.0	27
46	Chest computed tomography predicts microbiological burden and symptoms in pulmonary <i>Mycobacterium xenopi</i> . Respirology, 2013, 18, 92-101.	2.3	10
47	Aging, COPD, and Other Risk Factors Do Not Explain the Increased Prevalence of Pulmonary Mycobacterium avium Complex in Ontario. Chest, 2012, 141, 190-197.	0.8	53
48	Nontuberculous Mycobacterial Lung Infections in Ontario, Canada: Clinical and Microbiological Characteristics. Lung, 2010, 188, 289-299.	3.3	49
49	Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997 2003. Thorax, 2007, 62, 661-666.	5 . 6	282
50	Hypersensitivity Pneumonitis Reaction to Mycobacterium avium in Household Water. Chest, 2005, 127, 664-671.	0.8	151
51	Inpatient Care of Community-Acquired Pneumonia: The Effect of Antimicrobial Guidelines on Clinical Outcomes and Drug Costs in Canadian Teaching Hospitals. Canadian Respiratory Journal, 2004, 11, 131-137.	1.6	17
52	Mortality Prediction in PulmonaryMycobacterium KansasiiInfection and Human Immunodeficiency Virus. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 793-798.	5.6	32
53	Efficacy of exclusively oral antibiotic therapy in patients hospitalized with nonsevere community-acquired pneumonia: a retrospective study and meta-analysis. American Journal of Medicine, 2004, 116, 385-393.	1.5	22
54	A Systematic Review of the Clinical Significance of Pulmonary Mycobacterium kansasii Isolates in HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 36, 883-889.	2.1	31

THEODORE

#	Article	IF	CITATIONS
55	Obliterative Bronchiolitis Complicating Bone Marrow Transplantation. Seminars in Respiratory and Critical Care Medicine, 2003, 24, 531-542.	2.1	30
56	Tuberculosis Among Tibetan Refugee Claimants in Toronto. Chest, 2003, 124, 915-921.	0.8	24